Chris T. Williamson
Eli Lilly (United States)(US)Shelton State Community College(US)Tuscaloosa City Schools(US)
Publications by Year
Research Areas
Chromatin Remodeling and Cancer, Cancer Mechanisms and Therapy, Animal Virus Infections Studies, PARP inhibition in cancer therapy, Sarcoma Diagnosis and Treatment
Most-Cited Works
- → DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer(2015)2,165 cited
- → ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A(2016)379 cited
- → Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors(2020)239 cited
- → ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors(2010)190 cited
- → Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53(2012)126 cited
- → PREX: PeroxiRedoxin classification indEX, a database of subfamily assignments across the diverse peroxiredoxin family(2010)111 cited